What insurance policy changes affect code G21.11?

There are 2 tracked policy changes affecting code G21.11, including updates from Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G21.11?

Payers that have issued tracked updates for code G21.11 include: Blue Cross & Blue Shield of Mississippi.

How do I get notified when code G21.11 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G21.11. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G21.11?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

G21.11 Insurance Policy Changes

ICD-10 G21.11 is officially defined as "Neuroleptic induced parkinsonism." code G21.11 is referenced in 2 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G21.11 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Deep Brain Stimulation
Unilateral or bilateral deep brain stimulation of the thalamus may be considered medically necessary for disabling, medically unresponsive tremor due to essential tremor or Parkinson disease, and bilateral thalamic stimulation for tremor in both upper limbs. Unilateral or bilateral stimulation of the globus pallidus or subthalamic nucleus may be considered medically necessary for Parkinson disease and for chronic, intractable primary dystonia in individuals older than 7 years. Adaptive deep brain stimulation for Parkinson disease, deep brain stimulation for other movement disorders, cluster headaches, and the other psychiatric or neurologic disorders listed in the policy are considered investigational. A 06/05/2025 update added that adaptive deep brain stimulation for Parkinson disease is considered investigational, and a 09/16/2026 update changed the description of deep brain stimulation systems and removed ICD-9 procedure and diagnosis codes from the code reference, with the policy statements unchanged.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Apomorphine
BCBSMS requires prior authorization for apomorphine. Apokyn (apomorphine) is covered for acute, intermittent treatment of 'off' episodes in patients with advanced Parkinson's disease, while Onapgo (apomorphine) for motor fluctuations in adults with advanced Parkinson's disease is considered not medically necessary when other options covered by the Plan are available. The 09/01/2025 revision changed the policy title to Apomorphine, added the Onapgo not medically necessary statement, and added that services not approved through the BCBSMS PA review process are not medically necessary; the 12/02/2025 Pharmacy & Therapeutics review updated sources.

Watch G21.11

Get one email when a payer policy names G21.11, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Deep Brain Stimulation

Apomorphine

What insurance policy changes affect code G21.11?

Which payers have updated policy for code G21.11?

How do I get notified when code G21.11 policy changes?

Why do payers change policies for code G21.11?